{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:02Z","timestamp":1792800902843,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2022 Chongqing Research Innovation Program for Graduate Student of the First Affiliated Hospital of Chongqing Medical University","award":["CYB22199"],"award-info":[{"award-number":["CYB22199"]}],"id":[{"id":"https:\/\/ror.org\/033vnzz93","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372881"],"award-info":[{"award-number":["82372881"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303655"],"award-info":[{"award-number":["82303655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Biomedicine Key R&D Project","award":["CSTB2021TIAD-KPX0041"],"award-info":[{"award-number":["CSTB2021TIAD-KPX0041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A significant challenge in bladder cancer treatment is primary chemoresistance, in which cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a pivotal role. While the contributions of CAFs to tumor progression and drug resistance are well established, the precise molecular mechanisms by which they induce chemoresistance remain unclear. A comprehensive understanding of the effect of TME modulation\u2014particularly through CAFs\u2014on the chemotherapeutic response is crucial for developing effective strategies to overcome chemoresistance and improve patient survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Primary fibroblasts were isolated from paired clinical samples of bladder cancer tissues and adjacent normal tissues to identify key CAF-derived secretory factors. Bioinformatics analysis, semiquantitative RT\u2012qPCR, and dual-luciferase reporter assays were subsequently used to investigate the functional role and mechanistic basis of CXCL14 in chemoresistance. The therapeutic relevance of these findings was further evaluated through in vitro and in vivo models, including ex vivo patient-derived organoid (PDO) models, by assessing cisplatin sensitivity and validating therapeutic targeting of the CXCL14-CCR7-STAT3 axis with small molecule inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to normal fibroblasts and CAFs from nonchemoresistance groups, CAFs derived from cisplatin-resistant patients demonstrated significantly greater paracrine-mediated induction of chemoresistance. Mechanistically, CAF-secreted CXCL14 engaged CCR7 on bladder cancer cells, triggering STAT3 phosphorylation and consequently upregulating the DNA repair gene ERCC4 to promote cisplatin resistance. In vivo validation confirmed that pharmacological CCR7 or STAT3 inhibition markedly reversed chemoresistance and potentiated cisplatin-induced tumor cell death. Notably, STAT3 activation mediated the overexpression of the glycolytic enzymes HK2 and LDHA, resulting in greater glycolytic flux in resistant cells. This metabolic reprogramming further facilitated the transdifferentiation of normal fibroblasts into CXCL14-secreting CAFs, establishing a self-reinforcing feedback loop that sustains chemoresistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CXCL14\/CCR7\/STAT3 axis critically mediates cisplatin resistance in bladder cancer through dual modulation of DNA repair and glycolytic metabolism. Therapeutic cotargeting of this pathway with CCR7 or STAT3 inhibitors combined with cisplatin represents a promising strategy to overcome chemoresistance and improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03487-4","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:41:58Z","timestamp":1756813318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer"],"prefix":"10.1186","volume":"44","author":[{"given":"Tinghao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"3487_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3487_CR2","doi-asserted-by":"publisher","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Mo Q, Zhao X, Fan Q, Deng F, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68:100938.https:\/\/doi.org\/10.1016\/j.drup.2023.100938.","DOI":"10.1016\/j.drup.2023.100938"},{"key":"3487_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"18","author":"DM Jiang","year":"2021","unstructured":"Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021;18:104\u201314. https:\/\/doi.org\/10.1038\/s41585-020-00404-6.","journal-title":"Nat Rev Urol"},{"key":"3487_CR4","doi-asserted-by":"publisher","unstructured":"Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patan\u00e8 D, Grass GD, et al. Comparative effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive urothelial bladder cancer. Eur Urol Oncol. 2024.https:\/\/doi.org\/10.1016\/j.euo.2023.12.008.","DOI":"10.1016\/j.euo.2023.12.008"},{"key":"3487_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Mo Q, Zhao X, Fan Q, Deng F, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68: 100938. https:\/\/doi.org\/10.1016\/j.drup.2023.100938.","journal-title":"Drug Resist Updat"},{"key":"3487_CR6","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433.","journal-title":"J Clin Oncol"},{"key":"3487_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ajpath.2022.12.005","volume":"193","author":"T Yamashita","year":"2023","unstructured":"Yamashita T, Higashi M, Sugiyama H, Morozumi M, Momose S, Tamaru JI. Cancer antigen 125 expression enhances the gemcitabine\/cisplatin-resistant tumor microenvironment in bladder cancer. Am J Pathol. 2023;193:350\u201361. https:\/\/doi.org\/10.1016\/j.ajpath.2022.12.005.","journal-title":"Am J Pathol"},{"key":"3487_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"key":"3487_CR9","doi-asserted-by":"publisher","unstructured":"Mucciolo G, Araos HJ, Jihad M, Pinto TS, Manansala JS, Li W, Ashworth S, Lloyd EG, Cheng P, Luo W, et al. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell. 2024;42:101\u2013118.\nhttps:\/\/doi.org\/10.1016\/j.ccell.2023.12.002.","DOI":"10.1016\/j.ccell.2023.12.002"},{"key":"3487_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.798680","volume":"12","author":"M Wessolly","year":"2022","unstructured":"Wessolly M, Mairinger E, Borchert S, Bankfalvi A, Mach P, Schmid KW, Kimmig R, Buderath P, Mairinger FD. CAF-associated paracrine signaling worsens outcome and potentially contributes to chemoresistance in epithelial ovarian cancer. Front Oncol. 2022;12: 798680https:\/\/doi.org\/10.3389\/fonc.2022.798680.","journal-title":"Front Oncol"},{"key":"3487_CR11","doi-asserted-by":"publisher","unstructured":"Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G, Yin J, Liang X, Liu Z. Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell. 2022;40:1550\u20131565.\nhttps:\/\/doi.org\/10.1016\/j.ccell.2022.11.005.","DOI":"10.1016\/j.ccell.2022.11.005"},{"key":"3487_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41388-022-02540-2","volume":"42","author":"W Zeng","year":"2023","unstructured":"Zeng W, Xiong L, Wu W, Li S, Liu J, Yang L, Lao L, Huang P, Zhang M, Chen H, et al. CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype. Oncogene. 2023;42:224\u201337. https:\/\/doi.org\/10.1038\/s41388-022-02540-2.","journal-title":"Oncogene"},{"key":"3487_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1221-6","volume":"9","author":"SK Sagwal","year":"2018","unstructured":"Sagwal SK, Pasqual-Melo G, Bodnar Y, Gandhirajan RK, Bekeschus S. Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16. Cell Death Dis. 2018;9: 1179. https:\/\/doi.org\/10.1038\/s41419-018-1221-6.","journal-title":"Cell Death Dis"},{"key":"3487_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/carcin\/bgz151","volume":"41","author":"M Dedobbeleer","year":"2020","unstructured":"Dedobbeleer M, Willems E, Lambert J, Lombard A, Digregorio M, Lumapat PN, Di Valentin E, Freeman S, Goffart N, Scholtes F, et al. MKP1 phosphatase is recruited by CXCL12 in glioblastoma cells and plays a role in DNA strand breaks repair. Carcinogenesis. 2020;41:417\u201329. https:\/\/doi.org\/10.1093\/carcin\/bgz151.","journal-title":"Carcinogenesis"},{"key":"3487_CR15","doi-asserted-by":"publisher","unstructured":"Gowhari SA, Haleem AZ, Markov A, Valerievich YA, Ezzatifar F, Ahmadi M, Mohammad GS, Gholizadeh NJ. Chemokine CXCL14; a double-edged sword in cancer development. Int Immunopharmacol. 2021;97:107681.\nhttps:\/\/doi.org\/10.1016\/j.intimp.2021.107681.","DOI":"10.1016\/j.intimp.2021.107681"},{"key":"3487_CR16","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1158\/1078-0432.CCR-18-1294","volume":"25","author":"E Sj\u00f6berg","year":"2019","unstructured":"Sj\u00f6berg E, Meyrath M, Milde L, Herrera M, L\u00f6vrot J, H\u00e4gerstrand D, Frings O, Bartish M, Rolny C, Sonnhammer E, et al. A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer. Clin Cancer Res. 2019;25:3702\u201317. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1294.","journal-title":"Clin Cancer Res"},{"key":"3487_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/0008-5472.CAN-16-1615","volume":"77","author":"L Zhao","year":"2017","unstructured":"Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, Zhang Y, Yang H, Xuan Y, Yang Y, et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res. 2017;77:1369\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1615.","journal-title":"Cancer Res"},{"key":"3487_CR18","doi-asserted-by":"publisher","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173:515\u2013528.\nhttps:\/\/doi.org\/10.1016\/j.cell.2018.03.017.","DOI":"10.1016\/j.cell.2018.03.017"},{"key":"3487_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00741-6","volume":"12","author":"HW Lee","year":"2020","unstructured":"Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, Hong JH, Nam DH, Jeong BC, Park SH, et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020;12: 47. https:\/\/doi.org\/10.1186\/s13073-020-00741-6.","journal-title":"Genome Med"},{"key":"3487_CR20","doi-asserted-by":"publisher","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WR, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u20133587.\nhttps:\/\/doi.org\/10.1016\/j.cell.2021.04.048.","DOI":"10.1016\/j.cell.2021.04.048"},{"key":"3487_CR21","doi-asserted-by":"publisher","unstructured":"Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C, Tang M, Zhang Y, Xiang X, Tan L, et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 2024;42:1370\u20131385.\nhttps:\/\/doi.org\/10.1016\/j.ccell.2024.07.006.","DOI":"10.1016\/j.ccell.2024.07.006"},{"key":"3487_CR22","doi-asserted-by":"publisher","unstructured":"Park S, Karalis JD, Hong C, Clemenceau JR, Porembka MR, Kim IH, Lee SH, Wang SC, Cheong JH, Hwang TH. ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer. Clin. Cancer Res. 2023;29:1077\u20131085.\nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1897.","DOI":"10.1158\/1078-0432.CCR-22-1897"},{"key":"3487_CR23","doi-asserted-by":"publisher","unstructured":"McAndrews KM, Chen Y, Darpolor JK, Zheng X, Yang S, Carstens JL, Li B, Wang H, Miyake T, Correa DSP, et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 2022;12:1580\u20131597.\nhttps:\/\/doi.org\/10.1158\/2159-8290.CD-20-1484.","DOI":"10.1158\/2159-8290.CD-20-1484"},{"key":"3487_CR24","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383. https:\/\/doi.org\/10.1038\/onc.2011.384.","journal-title":"Oncogene"},{"key":"3487_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1604-0","volume":"20","author":"X Qin","year":"2019","unstructured":"Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, Xu Q, Shi J, Lu E, Chen W, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20: 12. https:\/\/doi.org\/10.1186\/s13059-018-1604-0.","journal-title":"Genome Biol"},{"key":"3487_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008616","volume":"16","author":"PJ McHugh","year":"2020","unstructured":"McHugh PJ. XPF-ERCC1: linchpin of DNA crosslink repair. PLoS Genet. 2020;16: e1008616. https:\/\/doi.org\/10.1371\/journal.pgen.1008616.","journal-title":"PLoS Genet"},{"key":"3487_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106367","volume":"140","author":"N Zuo","year":"2023","unstructured":"Zuo N, Ma L, Liu T, Hu W, Luo Y, Meng H, Ren Q, Deng Y, Wei L, Liu Q. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2023;140: 106367. https:\/\/doi.org\/10.1016\/j.oraloncology.2023.106367.","journal-title":"Oral Oncol"},{"key":"3487_CR28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","volume":"73","author":"M Song","year":"2021","unstructured":"Song M, He J, Pan QZ, Yang J, Zhao J, Zhang YJ, Huang Y, Tang Y, Wang Q, He J, et al. Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology. 2021;73:1717\u201335. https:\/\/doi.org\/10.1002\/hep.31792.","journal-title":"Hepatology"},{"key":"3487_CR29","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-12-1097","volume":"72","author":"S Vicent","year":"2012","unstructured":"Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, et al. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 2012;72:5744\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1097.","journal-title":"Cancer Res"},{"key":"3487_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579\u201396. https:\/\/doi.org\/10.1084\/jem.20162024.","journal-title":"J Exp Med"},{"key":"3487_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2024.05.007","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhao C, Li Y, Wu J, Wang F, Yu J, Wang Z, Gao Y, Zhao L, Liu Y, et al. FGD5 in basal cells induces CXCL14 secretion that initiates a feedback loop to promote murine mammary epithelial growth and differentiation. Dev Cell. 2024. https:\/\/doi.org\/10.1016\/j.devcel.2024.05.007.","journal-title":"Dev Cell"},{"key":"3487_CR32","doi-asserted-by":"publisher","unstructured":"Jaeger K, Bruenle S, Weinert T, Guba W, Muehle J, Miyazaki T, Weber M, Furrer A, Haenggi N, Tetaz T, et al. Structural basis for allosteric ligand recognition in the human CC chemokine receptor 7. Cell. 2019;178:1222\u20131230.\nhttps:\/\/doi.org\/10.1016\/j.cell.2019.07.028.","DOI":"10.1016\/j.cell.2019.07.028"},{"key":"3487_CR33","doi-asserted-by":"publisher","unstructured":"Kondo A, Osawa T. Establishment of an extracellular acidic pH culture system. J Vis Exp. 2017.\nhttps:\/\/doi.org\/10.3791\/56660.","DOI":"10.3791\/56660"},{"key":"3487_CR34","doi-asserted-by":"publisher","unstructured":"Gu X, Zhu Y, Su J, Wang S, Su X, Ding X, Jiang L, Fei X, Zhang W. Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression. Redox Biol. 2024;74:103209.https:\/\/doi.org\/10.1016\/j.redox.2024.103209.","DOI":"10.1016\/j.redox.2024.103209"},{"key":"3487_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03136-8","author":"X Wang","year":"2024","unstructured":"Wang X, Guo T, Niu L, Zheng B, Huang W, Xu H, Huang W. Engineered targeting OIP5 sensitizes bladder cancer to chemotherapy resistance via TRIP12-PPP1CB-YBX1 axis. Oncogene. 2024. https:\/\/doi.org\/10.1038\/s41388-024-03136-8.","journal-title":"Oncogene"},{"key":"3487_CR36","doi-asserted-by":"publisher","unstructured":"Augsten M, Sj\u00f6berg E, Frings O, Vorrink SU, Frijhoff J, Olsson E, Borg \u00c5, \u00d6stman A. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 2014;74:2999\u20133010.\nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2740.","DOI":"10.1158\/0008-5472.CAN-13-2740"},{"key":"3487_CR37","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1158\/0008-5472.CAN-10-0427","volume":"70","author":"EY Song","year":"2010","unstructured":"Song EY, Shurin MR, Tourkova IL, Gutkin DW, Shurin GV. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Res. 2010;70:4394\u2013401. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0427.","journal-title":"Cancer Res"},{"key":"3487_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021130","author":"T Lumpp","year":"2024","unstructured":"Lumpp T, St\u00f6\u00dfer S, Fischer F, Hartwig A, K\u00f6berle B. Role of epigenetics for the efficacy of cisplatin. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25021130.","journal-title":"Int J Mol Sci"},{"key":"3487_CR39","doi-asserted-by":"publisher","unstructured":"Van den Heuvel D, Kim M, Wondergem AP, van der Meer PJ, Witkamp M, Lambregtse F, Kim HS, Kan F, Apelt K, Kragten A, et al. A disease-associated XPA allele interferes with TFIIH binding and primarily affects transcription-coupled nucleotide excision repair. Proc Natl Acad Sci U S A. 2023;120:e2086107176.\nhttps:\/\/doi.org\/10.1073\/pnas.2208860120.","DOI":"10.1073\/pnas.2208860120"},{"key":"3487_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1348216","volume":"15","author":"R Shi","year":"2024","unstructured":"Shi R, Wang S, Jiang Y, Zhong G, Li M, Sun Y. ERCC4: a potential regulatory factor in inflammatory bowel disease and inflammation-associated colorectal cancer. Front Endocrinol (Lausanne). 2024;15: 1348216. https:\/\/doi.org\/10.3389\/fendo.2024.1348216.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3487_CR41","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.7150\/ijbs.79438","volume":"19","author":"TM Chang","year":"2023","unstructured":"Chang TM, Chiang YC, Lee CW, Lin CM, Fang ML, Chi MC, Liu JF, Kou YR. CXCL14 promotes metastasis of non-small cell lung cancer through ACKR2-depended signaling pathway. Int J Biol Sci. 2023;19:1455\u201370. https:\/\/doi.org\/10.7150\/ijbs.79438.","journal-title":"Int J Biol Sci"},{"key":"3487_CR42","doi-asserted-by":"publisher","unstructured":"Affinito A, Quintavalle C, Chianese RV, Roscigno G, Fiore D, D'Argenio V, Thomas G, Savarese A, Ingenito F, Cocca L, et al. MCT4-driven CAF-mediated metabolic reprogramming in breast cancer microenvironment is a vulnerability targetable by miR-425\u20135p. Cell Death Discov. 2024;10:140.\nhttps:\/\/doi.org\/10.1038\/s41420-024-01910-x.","DOI":"10.1038\/s41420-024-01910-x"},{"key":"3487_CR43","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1038\/s44319-024-00180-z","volume":"25","author":"L Ippolito","year":"2024","unstructured":"Ippolito L, Duatti A, Iozzo M, Comito G, Pardella E, Lorito N, Bacci M, Pranzini E, Santi A, Sandrini G, et al. Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer. EMBO Rep. 2024;25:3506\u201331. https:\/\/doi.org\/10.1038\/s44319-024-00180-z.","journal-title":"EMBO Rep"},{"key":"3487_CR44","doi-asserted-by":"publisher","unstructured":"Linares JF, Cid-Diaz T, Duran A, Osrodek M, Martinez-Ordo\u00f1ez A, Reina-Campos M, Kuo HH, Elemento O, Martin ML, Cordes T, et al. The lactate-NAD(+) axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022;39:110792.\nhttps:\/\/doi.org\/10.1016\/j.celrep.2022.110792.","DOI":"10.1016\/j.celrep.2022.110792"},{"key":"3487_CR45","doi-asserted-by":"publisher","unstructured":"Kitamura F, Semba T, Yasuda-Yoshihara N, Yamada K, Nishimura A, Yamasaki J, Nagano O, Yasuda T, Yonemura A, Tong Y, et al. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.163022.","DOI":"10.1172\/jci.insight.163022"},{"key":"3487_CR46","doi-asserted-by":"publisher","unstructured":"Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kwak C, et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 2019. https:\/\/doi.org\/10.7554\/eLife.50663.","DOI":"10.7554\/eLife.50663"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03487-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:02:49Z","timestamp":1756857769000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03487-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3487"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03487-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}